Title:
OPHTHALMIC LIPOSOME CAPABLE OF PENETRATING CORNEA AND TARGETING RETINA, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
Document Type and Number:
WIPO Patent Application WO/2022/037063
Kind Code:
A1
Abstract:
The present disclosure relates to an ophthalmic liposome capable of penetrating a cornea and targeting a retina, a preparation method therefore and an application thereof. The ophthalmic liposome is a liposome which is made of biocompatible lipid material and encapsulates an anti-VEGF drug, and whose surface is connected to cell-penetrating peptide (CPP) and hyaluronic acid (HA). According to the present disclosure, the anti-VEGF drug is encapsulated by the liposome, thereby effectively mitigating the instability of the anti-VEGF drug. Corneal penetration is enhanced through the amphiphilicity of the liposome, and the surface of the liposome is covalently linked to the cell-penetrating peptide (CPP) which has penetration effects and the hyaluronic acid (HA) which targets the retina. It is found that the liposome prepared can significantly increase corneal penetration and accumulation in the ocular fundus of the drug by means of eye drop instillation, thereby enhancing drug concentration at a lesion site and significantly improving the treatment effect.
Inventors:
DING XUEYING (CN)
XU NAN (CN)
ZHANG SHUYUE (CN)
LIU KUN (CN)
GAO SHEN (CN)
DING BAOYUE (CN)
WANG ZHUO (CN)
HE MEI (CN)
TAI ZONGGUANG (CN)
XU NAN (CN)
ZHANG SHUYUE (CN)
LIU KUN (CN)
GAO SHEN (CN)
DING BAOYUE (CN)
WANG ZHUO (CN)
HE MEI (CN)
TAI ZONGGUANG (CN)
Application Number:
PCT/CN2021/082922
Publication Date:
February 24, 2022
Filing Date:
March 25, 2021
Export Citation:
Assignee:
SHANGHAI GENERAL HOSPITAL (CN)
International Classes:
A61K9/00; A61K47/61; A61K39/395; A61K45/00; A61K47/62; A61K47/69; A61P9/10; A61P27/02
Foreign References:
| CN108976288A | 2018-12-11 | |||
| CN110339367A | 2019-10-18 | |||
| CN102091036A | 2011-06-15 |
Other References:
GAN, LI ET AL.: "Hyaluronan-modified Core-shell Liponanoparticles Targeting CD 44-positive Retinal Pigment Epithelium Cells via Intravitreal Injection", BIOMATERIALS, vol. 34, 13 May 2013 (2013-05-13), pages 5978 - 5987, XP028552027, DOI: 10.1016/j.biomaterials.2013.04.035
Attorney, Agent or Firm:
SHANGHAI ZHUOYANG INTELLECTUAL PROPERTY AGENT FIRM (CN)
Download PDF:
Previous Patent: ON-LINE COLOR DIFFERENCE MEASUREMENT SYSTEM AND METHOD
Next Patent: DEODORIZATION DEVICE
Next Patent: DEODORIZATION DEVICE